SUMM.L Regulatory News (SUMM)

2 Aug 2005 07:00

VASTox plc02 August 2005 For immediate release 2 August 2005 VASTox plc ("VASTox" or "the Company") CHANGE OF ADVISOR Oxford, UK: 2 August 2005 - VASTox plc (AIM: VOX), the drug discovery andservices business, is pleased to announce today that, with immediate effect, ithas appointed Evolution Securities Limited as the Company's nominated adviserand broker. For more information please contact: VASTox plcSteven Lee, Chief Executive Officer 01235 443 901 07766 913 898 Evolution Securities 020 7071 4391 Matt Wood, Corporate Finance Buchanan CommunicationsTim Anderson / Mary-Jane Johnson 020 7466 5000 Notes for Editors: About VASTox plc VASTox is a chemical genomics technology company that provides services to thepharmaceutical industry and discovers and develops proprietary novel drugs. Thecompany's technology platform aims to use high volume, high content screeningusing zebrafish and fruitflies to provide a high level of predictability of theefficacy and toxicity of potential drug compounds in humans which has thepotential to dramatically decrease the time and cost of drug discovery anddevelopment. VASTox was formed in January 2003, from the University of Oxford,by some of the UK's foremost scientists who have taken a highly creativeapproach to the problems involved in drug discovery and who have a proven recordin delivering technological excellence. The company listed on the London StockExchange AIM in October 2004. This information is provided by RNS The company news service from the London Stock Exchange